ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0647

Clinical Associations and Outcomes of Pericarditis in Systemic Lupus Erythematosus
Abstract Number: 2647

Clinical Characteristics , Treatment Outcomes and Predictors of Mortality in a DADA2 Cohort of 101 Patients
Abstract Number: 0147

Clinical Characteristics and Biomarkers Associated with Detectable High-Sensitivity Cardiac Troponin in Patients with Rheumatoid Arthritis
Abstract Number: 2497

Clinical Characteristics and Outcomes of Hydralazine-induced ANCA-associated Vasculitis. a Single Center Retrospective Cohort Analysis from the US
Abstract Number: 2511

Clinical Characteristics and Outcomes of Patients with Clinically Isolated Aortitis
Abstract Number: 2392

Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus When Accompanying Myositis: A Retrospective Real-Life Study
Abstract Number: 1508

Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients
Abstract Number: 0339

Clinical Characteristics Associated with Inpatient Mortality in Dermatomyositis Patients: A Single Center Retrospective Cohort Study
Abstract Number: 0908

Clinical Characteristics of Patients with High SLE-specific and High Multitrait Polygenic Risk – an Investigation of SLE Risk Loci
Abstract Number: 2494

Clinical Characteristics, Predictors for Mortality and Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score on Survival in ANCA-associated Vasculitis in Hong Kong : A Multi-centre Retrospective Cohort Study
Abstract Number: 2381

Clinical Characteristics, Readmission Rates, and Outcomes in Lupus Patients with and Without Nephritic Involvement: Analysis from a National Database
Abstract Number: 1151

Clinical Characterization and Recurrence Prediction Model for Immune-Mediated Necrotizing Myopathy
Abstract Number: 0754

Clinical Characterization of Aortitis and Periaortitis in a Cohort of 134 Patients from a Single Universitary Center. A Model-based Cluster Analysis
Abstract Number: 1365

Clinical Conditions Associated with Genetic Predisposition to Rheumatoid Arthritis in Real-World Settings
Abstract Number: 0627

Clinical Conditions Associated with Presence of a High-titer Antinuclear Antibody in Individuals Without Autoimmune Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].